Effects Of Heluosugan Capsule On Mapk Pathway In Hepatic Stellate Cells (HSC)

Objective: Study the activation of ERK/JNK in the activated hepatic stellate cell(HSC)mitogen activated protein kinase(MAPKs) pathway and explore the specific mechanisms of Heluoshugan capsule for anti-liver fibrosis treatment.Method:Preparation of SD rats with liver fibrosis model. The drug group with 1g/kg/d Heluoshugan capsules, 2 times, gavage; the control group with an equal volume of saline irrigation. 30 days later, take the inferior vena cava blood centrifugation,separate serum, test ALT, AST, ALP index and make the liver tissue pathological testing. Adopt blind method, using the above-mentioned 10% of drug serum-free culture-activated HSCs 24h later, we detected each group HSCs P-ERK,P-JNK protein levels with Western blot test.Result:Result showed that Heluoshugan could improve the pathological changes of liver tissue, and significantly decreased the level of ALT,AST,ALP,P <0.05.The expression levels of p-ERK,P-JNK protein in rat liver fibrosis, intervening by the Heluoshugan capsule serum(D group)compared with liver fibrosis model group (C group), was significantly lower (P <0.05); normal rats by the Heluoshugan capsule serum(B group)compared with normal control group (A group), p-ERK,P-JNK protein levels also significantly reduced in comparison (P <0.05).Conclusion: Through influencing the expression of activated HSCs phosphorylation of extracellular signal-regulated protein kinase (p-ERK) and phosphorylated N-terminal protein kinase (p-JNK), Heluoshugan capsule block MAPK signaling pathway and inhibit hepatic stellate cells division and proliferation, it may be an important way of anti-liver fibrosis.